Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
From MaRDI portal
Publication:4666639
DOI10.1111/j.0006-341X.1999.00746.xzbMath1059.62724WikidataQ73789815 ScholiaQ73789815MaRDI QIDQ4666639
Publication date: 13 April 2005
Published in: Biometrics (Search for Journal in Brave)
Applications of statistics to biology and medical sciences; meta analysis (62P10) Testing in survival analysis and censored data (62N03)
Related Items
Monitoring phase II comparative clinical trials with two endpoints and penalty for adverse events, Some geometric methods for constructing decision criteria based on two-dimensional parame\-ters, Ethical issues in oncology biostatistics, An Adaptive Approach to Implementing Bivariate Group Sequential Clinical Trial Designs, A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases, Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
Uses Software
Cites Work
- Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations
- Discrete Sequential Boundaries for Clinical Trials
- Interim analyses with repeated measurements in a sequential clinical trial
- Group Sequential Tests for Bivariate Response: Interim Analyses of Clinical Trials with Both Efficacy and Safety Endpoints
- Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
- Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
- Coupled Error Spending Functions for Parallel Bivariate Sequential Tests
- Corrigendum
- Algorithm 706: DCUTRI: an algorithm for adaptive cubature over a collection of triangles
- Group-Sequential Analysis Incorporating Covariate Information
- Group Sequential Distribution-Free Methods for the Analysis of Multivariate Observations
- Guidelines for Monitoring Efficacy and Toxicity Responses in Clinical Trials
- Bivariate Sequential Designs for Phase II Trials
